Cell lines

human multiple myeloma (MM)

Preparation method

The solubility of this compound in DMSO is >21.6 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

0.1-10 μM

Applications

In human multiple myeloma (MM), AS703026 (5, 0.5, and 0.1 μM) inhibited growth and survival of MM cells and cytokine-induced osteoclast differentiation. In MM cells, AS703026 inhibited the growth of MM cell lines in a dose-dependent manner, with IC50s ranging from 0.005 to 2 μM. The IC50s of AS703026 against INA-6, U266, H929 cells are 10 nM, 5 nM, and 200 nM, respectively. AS703026 induced apoptosis and modulated the cell cycle profile. AS703026 (10 μmol/L) inhibited ERK pathway, proliferation, and transformation in cetuximab-resistant D-MUT cells.

Animal models

CB17 SCID mice bearing human H929 MM xenografts

Dosage form

Oral administration, 15, 30 mg/kg, twice daily

Application

In the human H929 MM xenograft model in CB17 SCID mice, AS703026 (15, 30 mg/kg, twice daily, p.o.) significantly inhibited tumor growth in a time-dependent manner, with no significant body weight loss. AS703026-treated H929 tumors from mice exhibited increased cleaved caspase 3 and TUNEL. AS703026 treatment significantly reduced the percentage of CD34+ cells and microvascular density in H929 tumors. AS703026 (10 mg/kg, p.o.) inhibited tumor growth of cetuximab-resistant tumor attributed by K-ras mutation.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

IC50: ranging from 0.005 to 2 μM for the growth of MM cell lines

The MEK/ERK pathway transmits mitogenic signals to the nucleus and thus regulates the expression of genes that are critical for survival, proliferation, and differentiation. This pathway is often upregulated in cancer as result of oncogenic mutations. MEK is a crucial kinase in this pathway and has been targeted for the therapeutic agents development that block the MEK/ERK signaling cascade. AS 703026 is a novel small molecule MEK inhibitor.

In vitro: AS 703026 binds to the distinctive MEK allosteric site and therefore exhibits exquisite kinase selectivity. The AS 703026 binding to MEK is independent of ATP, and results in enzyme inhibition by prevention of activation. This inhibitor shows strong antiproliferative effect on tumor cell lines bearing oncogenic mutations or amplifications along the MEK/ERK pathway [1].

In vivo: In relevant mouse xenograft models, AS 703026 inhibits tumor growth after oral administration. The effect on tumor growth is dose-dependant and correlates with target modulation in both tumors and blood [1].

Clinical trial: 16 patients were enrolled in the trial. 10 and 6 patients were treated daily with 45 and 60 mg of AS 703026 plus FOLFIRI, respectively. The MTD was considered to be 45 mg/day. Of the 15 patients in the efficacy analysis group, 2 patients had partial response, 9 patients had stable disease, 3 patients had progressive disease as their best overall response and 1 patient could not be evaluated.

Reference:
[1] Goutopoulos A, Askew BC, Bankston D, Clark A, Dhanabal M, Dong R, Fischer D, Healey B, Jiang X, Josephson K, Lin J, Ma J, Noonan T, Qiu D, Rocha C, Romanelli A, Shutes A, Spooner E, Tian H, H Y.  AS703026: a novel allosteric MEK inhibitor. AACR Annual meeting. 2009 Abstract#4776.
[2] Macarulla T, Cervantes A, Tabernero J et al.  Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer. Br J Cancer. 2015 Jun 9;112(12):1874-81.